Latest

The MarketReader Minute

πŸ’Š Incyte Corp Drops on Project Shifts, Blueprint Medicines Beats Revenue Estimates, Moderna and Biogen Edge Down Ahead of Earnings Reports | Biotech Sector Insights

Repligen Corporation announced its acquisition of Tantti Laboratory, which is expected to enhance its capabilities and positively impact adjusted margins and earnings per share by 2026. The company also provided updated financial guidance for 2024, projecting adjusted EPS between $1.42 and $1.49.

lock-1